An inhibitor of NLRP3 inflammasome activation
Related Products
Alternative(s)
17510MCC950
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

MCC950 (sodium salt)

Item No. 34762

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide, monosodium salt
CAS Number
256373-96-3
Synonyms
  • CP 456,773
Molecular Formula
C20H23N2O5S • Na
Formula Weight
426.5
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlEthanol: 10 mg/mlPBS (pH 7.2): 1 mg/ml
SMILES
O=C([N-]S(=O)(C1=CC(C(C)(O)C)=CO1)=O)NC2=C(CCC3)C3=CC4=C2CCC4.[Na+]
InChi Code
InChI=1S/C20H24N2O5S.Na/c1-20(2,24)14-10-17(27-11-14)28(25,26)22-19(23)21-18-15-7-3-5-12(15)9-13-6-4-8-16(13)18;/h9-11,24H,3-8H2,1-2H3,(H2,21,22,23);/q;+1/p-1
InChi Key
LFQQNXFKPNZRFT-UHFFFAOYSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $32

    Add

    5 mg

    $71

    Add

    10 mg

    $125

    Add

    25 mg

    $271

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    MCC950 is an inhibitor of NOD-like receptor protein 3 (NLRP3) inflammasome activation.1 It inhibits ATP-induced IL-1β release in LPS-primed mouse bone marrow-derived macrophages (BMDMs; IC50 = 7.5 nM), as well as cytosolic LPS-induced IL-1β release in Pam3CSK4-primed mouse BMDMs at 0.1 and 1 µM, indicating inhibition of both canonical and non-canonical NLRP3 inflammasome activation, respectively. MCC950 is selective for NLRP3 over NLRC4 and absent in melanoma 2 (AIM2) inflammasomes and does not inhibit LPS-induced NLRP3 priming in mouse BMDMs at 10 µM. It reduces ox-LDL-induced increases in caspase-1 activity and inhibits pyroptosis in THP-1 macrophages when used at a concentration of 1 µM.2 MCC950 (10 mg/kg) reduces myocardial fibrosis in mice following myocardial infarction induced by left coronary artery ligation.3 It improves forelimb grip strength and reduces spinal edema in a mouse model of spinal crush injury at the same dose.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Coll, R.C., Robertson, A.A.B., Chae, J.J., et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21(3), 248-255 (2015).

    2. Zeng, W., Wu, D., Sun, Y., et al. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating infammation and pyroptosis in macrophages. Sci. Rep. 11(1), 19305 (2021).

    3. Gao, R., Shi, H., Chang, S., et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. Int. Immunopharmacol. 74, 105575 (2019).

    4. Jiao, J., Zhao, G., Wang, Y., et al. MCC950, a selective inhibitor of NLRP3 inflammasome, reduces the inflammatory response and improves neurological outcomes in mice model of spinal cord injury. Front. Mol. Biosci. 7, 37 (2020).